Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic

ERNA-101Positive

AI Analysis

Summary

Ernexa Therapeutics appointed Dr. Robert J. Spiegel as an accomplished oncology drug developer to strengthen the company ahead of clinical development of ERNA-101, which demonstrated complete tumor clearance and 100% survival in combination with anti-PD-1 therapy.

Clinical Trial Data

Primary Endpoint

Met

Importance:5/10

Sentiment:

0.70

managementoncologydrug developmentclinical advancementtumor clearance

Related Companies

$ERNAW

Read the original article

Published by GlobeNewswire Clinical Studies on October 1, 2026 1:20 PM

Read Original